Veterinary Orthobiologics Market - Global Industry Size, Share, Trends, Opportunity, & Forecast Segmented By Product, By Animal, By Application, By Delivery Mode, By End User, By Region & Competition, 2021-2031F

Description

The Global Veterinary Orthobiologics Market is projected to expand from USD 787.27 Million in 2025 to USD 1312.36 Million by 2031, achieving a CAGR of 8.89%. Veterinary orthobiologics encompass biological substances like stem cells, platelet-rich plasma, and bone grafts, which veterinarians use to regenerate tissue and repair injured tendons, ligaments, and bones. The market's growth is primarily fueled by the increasing prevalence of osteoarthritis in aging companion animals and a growing willingness among pet owners to pay for premium healthcare services. This demand for advanced medical intervention is evidenced by significant industry expenditure; according to the American Pet Products Association, sales for veterinary care and products in the United States hit 39.8 billion dollars in 2024, highlighting the financial commitment supporting the adoption of regenerative therapies.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 787.27 Million
Market Size 2031	USD 1312.36 Million
CAGR 2026-2031	8.89%
Fastest Growing Segment	Platelet-Rich Plasma (PRP)
Largest Market	North America

However, the market faces a substantial hurdle regarding the high costs associated with these treatments. Many orthobiologic procedures remain financially out of reach for the average pet owner, and the scarcity of comprehensive insurance coverage for regenerative therapies in specific regions further restricts accessibility. Consequently, these financial constraints constitute a major challenge that could limit the widespread implementation of these solutions and decelerate the overall momentum of market growth.

Market Driver

The escalating prevalence of veterinary musculoskeletal and orthopedic disorders, significantly worsened by rising rates of pet obesity, acts as a primary catalyst for market expansion. As companion animals carry excess weight, mechanical stress on their joints increases, resulting in a higher frequency of osteoarthritis and ligament injuries that necessitate regenerative interventions. Data from the Association for Pet Obesity Prevention's '2024 Pet Obesity & Nutrition Opinion Survey', released in April 2025, indicates that 35% of dog owners and 33% of cat owners classified their pets as overweight or obese, representing a troubling year-over-year rise. This upward trend in weight-related health issues directly correlates with the surging demand for orthobiologic therapies, such as stem cells and platelet-rich plasma, which provide effective management for chronic joint deterioration.

Concurrently, the growing trend of pet humanization is fundamentally transforming the economic landscape of veterinary care. Owners increasingly regard their pets as essential family members, fueling a willingness to pursue advanced, frequently expensive medical treatments to ensure longevity and quality of life. The American Pet Products Association's '2025 State of the Industry Report', published in March 2025, reveals that pet ownership has broadened significantly, with 94 million U.S. households now owning at least one pet. This expanding base of dedicated owners creates the necessary market scale for sustained investment in novel regenerative technologies. Illustrating this rapid sector innovation, Gallant Therapeutics secured 18 million dollars in Series B funding in July 2025 to hasten the commercialization of its off-the-shelf stem cell therapies, underscoring strong financial confidence in the future of veterinary orthobiologics.

Market Challenge

The prohibitive cost of treatment represents a major obstacle to the expansion of the veterinary orthobiologics sector. These regenerative therapies frequently entail complex processing and specialized application, leading to high prices that are generally passed directly to the pet owner. Because veterinary healthcare in many primary markets operates predominantly on a fee-for-service basis, these significant out-of-pocket expenses often make such options inaccessible to the average client. This financial reality effectively confines the addressable market to a narrow demographic of affluent pet owners, preventing the procedure volume required to drive rapid industry growth.

This economic barrier is severely aggravated by the limited penetration of pet health insurance, which fails to bridge the affordability gap for most households. Without comprehensive coverage to offset these expenses, the market struggles to transition from niche usage to mass adoption. According to the North American Pet Health Insurance Association, the total number of insured pets in North America reached 7.03 million in 2025. This figure suggests that the vast majority of owners lack the financial safety net needed to fund premium regenerative procedures, directly dampening market volume and revenue velocity.

Market Trends

The market is observing a significant Shift Toward Allogeneic "Off-the-Shelf" Stem Cell Therapies, propelled by the urgent requirement for scalable, standardized treatments for common inflammatory diseases. In contrast to autologous methods that necessitate surgical extraction and processing, these manufactured therapies provide immediate availability and consistent dosing, meeting high-volume clinical needs in general practice. This demand is heavily underscored by the prevalence of difficult-to-treat conditions requiring advanced intervention; according to a July 2025 DVM360 article titled 'Veterinary stem cell therapy advances toward FDA approval with $18M in funding', refractory feline chronic gingivostomatitis alone affects up to 26% of domestic cats, creating a substantial addressable market for these novel, ready-to-use regenerative solutions.

Simultaneously, there is a distinct Expansion of Regenerative Medicine in Equine Sports Performance, where orthobiologics are becoming standard protocols for managing athletic injuries. High-value performance horses demand rapid, effective recovery strategies for tendon and ligament issues, prompting specialized veterinary centers to integrate these therapies into their core services to prolong competitive careers. Highlighting this increasing adoption rate within elite facilities, a VetStem press release from October 2025 titled 'Tryon Equine Hospital Surpasses 200 VetStem Regenerative Medicine Cases' noted that a single leading equine referral center successfully completed over 200 regenerative procedures, signaling broader industry acceptance and the commercial viability of these treatments in the equine sector.

Key Market Players

Zoetis Services LLC
Boehringer Ingelheim International GmbH
Ardent Animal Health
Enso Discoveries, LLC
VetStem, Inc
MEDREGO LLC
Arthrex, Inc.
Hilltop Biosciences
Enovis Corporation
Dechra Pharmaceuticals Limited

Report Scope

In this report, the Global Veterinary Orthobiologics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Veterinary Orthobiologics Market, By Product

Stem Cells
Platelet-rich Plasma (PRP)
Other

Veterinary Orthobiologics Market, By Animal

Canine
Equine
Others

Veterinary Orthobiologics Market, By Application

Osteoarthritis
Degenerative Joint Disease
Other

Veterinary Orthobiologics Market, By Delivery Mode

Intra-muscular/Intra-lesional
Intra-articular
Others

Veterinary Orthobiologics Market, By End User

Veterinary Hospitals
Veterinary Clinics
Others

Veterinary Orthobiologics Market, By Region

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Veterinary Orthobiologics Market.

Available Customizations:

Global Veterinary Orthobiologics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Veterinary Orthobiologics Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Product (Stem Cells, Platelet-rich Plasma (PRP), Other)
- 5.2.2. By Animal (Canine, Equine, Others)
- 5.2.3. By Application (Osteoarthritis, Degenerative Joint Disease, Other)
- 5.2.4. By Delivery Mode (Intra-muscular/Intra-lesional, Intra-articular, Others)
- 5.2.5. By End User (Veterinary Hospitals, Veterinary Clinics, Others)
- 5.2.6. By Region
- 5.2.7. By Company (2025)
5.3. Market Map

6. North America Veterinary Orthobiologics Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Product
- 6.2.2. By Animal
- 6.2.3. By Application
- 6.2.4. By Delivery Mode
- 6.2.5. By End User
- 6.2.6. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Veterinary Orthobiologics Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Product
    - 6.3.1.2.2. By Animal
    - 6.3.1.2.3. By Application
    - 6.3.1.2.4. By Delivery Mode
    - 6.3.1.2.5. By End User
- 6.3.2. Canada Veterinary Orthobiologics Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Product
    - 6.3.2.2.2. By Animal
    - 6.3.2.2.3. By Application
    - 6.3.2.2.4. By Delivery Mode
    - 6.3.2.2.5. By End User
- 6.3.3. Mexico Veterinary Orthobiologics Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Product
    - 6.3.3.2.2. By Animal
    - 6.3.3.2.3. By Application
    - 6.3.3.2.4. By Delivery Mode
    - 6.3.3.2.5. By End User

7. Europe Veterinary Orthobiologics Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Product
- 7.2.2. By Animal
- 7.2.3. By Application
- 7.2.4. By Delivery Mode
- 7.2.5. By End User
- 7.2.6. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Veterinary Orthobiologics Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Product
    - 7.3.1.2.2. By Animal
    - 7.3.1.2.3. By Application
    - 7.3.1.2.4. By Delivery Mode
    - 7.3.1.2.5. By End User
- 7.3.2. France Veterinary Orthobiologics Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Product
    - 7.3.2.2.2. By Animal
    - 7.3.2.2.3. By Application
    - 7.3.2.2.4. By Delivery Mode
    - 7.3.2.2.5. By End User
- 7.3.3. United Kingdom Veterinary Orthobiologics Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Product
    - 7.3.3.2.2. By Animal
    - 7.3.3.2.3. By Application
    - 7.3.3.2.4. By Delivery Mode
    - 7.3.3.2.5. By End User
- 7.3.4. Italy Veterinary Orthobiologics Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Product
    - 7.3.4.2.2. By Animal
    - 7.3.4.2.3. By Application
    - 7.3.4.2.4. By Delivery Mode
    - 7.3.4.2.5. By End User
- 7.3.5. Spain Veterinary Orthobiologics Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Product
    - 7.3.5.2.2. By Animal
    - 7.3.5.2.3. By Application
    - 7.3.5.2.4. By Delivery Mode
    - 7.3.5.2.5. By End User

8. Asia Pacific Veterinary Orthobiologics Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Product
- 8.2.2. By Animal
- 8.2.3. By Application
- 8.2.4. By Delivery Mode
- 8.2.5. By End User
- 8.2.6. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Veterinary Orthobiologics Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Product
    - 8.3.1.2.2. By Animal
    - 8.3.1.2.3. By Application
    - 8.3.1.2.4. By Delivery Mode
    - 8.3.1.2.5. By End User
- 8.3.2. India Veterinary Orthobiologics Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Product
    - 8.3.2.2.2. By Animal
    - 8.3.2.2.3. By Application
    - 8.3.2.2.4. By Delivery Mode
    - 8.3.2.2.5. By End User
- 8.3.3. Japan Veterinary Orthobiologics Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Product
    - 8.3.3.2.2. By Animal
    - 8.3.3.2.3. By Application
    - 8.3.3.2.4. By Delivery Mode
    - 8.3.3.2.5. By End User
- 8.3.4. South Korea Veterinary Orthobiologics Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Product
    - 8.3.4.2.2. By Animal
    - 8.3.4.2.3. By Application
    - 8.3.4.2.4. By Delivery Mode
    - 8.3.4.2.5. By End User
- 8.3.5. Australia Veterinary Orthobiologics Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Product
    - 8.3.5.2.2. By Animal
    - 8.3.5.2.3. By Application
    - 8.3.5.2.4. By Delivery Mode
    - 8.3.5.2.5. By End User

9. Middle East & Africa Veterinary Orthobiologics Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Product
- 9.2.2. By Animal
- 9.2.3. By Application
- 9.2.4. By Delivery Mode
- 9.2.5. By End User
- 9.2.6. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Veterinary Orthobiologics Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Product
    - 9.3.1.2.2. By Animal
    - 9.3.1.2.3. By Application
    - 9.3.1.2.4. By Delivery Mode
    - 9.3.1.2.5. By End User
- 9.3.2. UAE Veterinary Orthobiologics Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Product
    - 9.3.2.2.2. By Animal
    - 9.3.2.2.3. By Application
    - 9.3.2.2.4. By Delivery Mode
    - 9.3.2.2.5. By End User
- 9.3.3. South Africa Veterinary Orthobiologics Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Product
    - 9.3.3.2.2. By Animal
    - 9.3.3.2.3. By Application
    - 9.3.3.2.4. By Delivery Mode
    - 9.3.3.2.5. By End User

10. South America Veterinary Orthobiologics Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Product
- 10.2.2. By Animal
- 10.2.3. By Application
- 10.2.4. By Delivery Mode
- 10.2.5. By End User
- 10.2.6. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Veterinary Orthobiologics Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Product
    - 10.3.1.2.2. By Animal
    - 10.3.1.2.3. By Application
    - 10.3.1.2.4. By Delivery Mode
    - 10.3.1.2.5. By End User
- 10.3.2. Colombia Veterinary Orthobiologics Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Product
    - 10.3.2.2.2. By Animal
    - 10.3.2.2.3. By Application
    - 10.3.2.2.4. By Delivery Mode
    - 10.3.2.2.5. By End User
- 10.3.3. Argentina Veterinary Orthobiologics Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Product
    - 10.3.3.2.2. By Animal
    - 10.3.3.2.3. By Application
    - 10.3.3.2.4. By Delivery Mode
    - 10.3.3.2.5. By End User

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Veterinary Orthobiologics Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Zoetis Services LLC
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Boehringer Ingelheim International GmbH
15.3. Ardent Animal Health
15.4. Enso Discoveries, LLC
15.5. VetStem, Inc
15.6. MEDREGO LLC
15.7. Arthrex, Inc.
15.8. Hilltop Biosciences
15.9. Enovis Corporation
15.10. Dechra Pharmaceuticals Limited